{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:32:36Z","timestamp":1790332356496,"version":"4.1.0"},"reference-count":25,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We aimed to measure the effect of raltegravir (RAL) on insulin sensitivity and surrogates of cardiovascular risk in healthy HIV-seronegative volunteers compared to that of lopinavir\/r (LPV\/r), a positive control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An open-label, two phase crossover study in HIV-negative male subjects randomized 1:1 to receive either 2 weeks of LPV\/r followed by a 2-week washout period and 2 weeks of RAL, or RAL initially followed by LPV\/r. A hyperinsulinaemic euglycaemic clamp was performed prior to and following each 2-week dosing phase. Fasting samples for lipids, adiponectin, leptin, vascular inflammatory biomarkers and CD36 were also taken.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 16 subjects completed the study. At the baseline visit the mean insulin-stimulated glucose disposal per unit insulin (M\/I) was 7.97 and 8.30 for LPV\/r and RAL, respectively. The mean (sem) percentage change from baseline was -16.10% (3.84) after 2 weeks of LPV\/r and -0.43% (4.83) after 2 weeks of RAL. Absolute M\/I was 25% lower for LPV\/r than for RAL ( P=0.001). Triglycerides and total cholesterol rose significantly with LPV\/r (+0.5 mmol\/l, P=0.002 and +0.4 mmol\/l, P&lt;0.0001), but were unchanged with RAL. Proathrogenic lipid subfractions of low-density lipoprotein (LDL) cholesterol increased with LPV\/r and were unaffected with RAL. LDL peak and mean particle diameter and LDL I significantly decreased with LPV\/r ( P&lt;0.05), and trend of increased LDL III was detected. High-sensitivity C-reactive protein declined with RAL (-0.2 mg\/l, P=0.043) but was elevated after LPV\/r (+0.25 mg\/l, P=0.03).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>RAL was not associated with measurable change in glycaemic, metabolic or inflammatory effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3851\/imp3098","type":"journal-article","created":{"date-parts":[[2016,10,6]],"date-time":"2016-10-06T05:09:49Z","timestamp":1475730589000},"page":"145-151","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":11,"title":["An Open-Label, Randomized Study of the Impact on Insulin Sensitivity, Lipid Profile and Vascular Inflammation by Treatment with Lopinavir\/Ritonavir or Raltegravir in HIV-Negative Male Volunteers"],"prefix":"10.1177","volume":"22","author":[{"given":"Paul","family":"Randell","sequence":"first","affiliation":[{"name":"St Stephen's AIDS Trust, Chelsea and Westminster Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akil","family":"Jackson","sequence":"additional","affiliation":[{"name":"St Stephen's AIDS Trust, Chelsea and Westminster Hospital, London, UK"},{"name":"Present: Institute of Translational Medicine, University of Liverpool, Liverpool, UK"},{"name":"Present: Gilead Sciences Ltd., London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Milinkovic","sequence":"additional","affiliation":[{"name":"St Stephen's AIDS Trust, Chelsea and Westminster Hospital, London, UK"},{"name":"Present: Research Department of Infection and Population Health, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Boffito","sequence":"additional","affiliation":[{"name":"St Stephen's AIDS Trust, Chelsea and Westminster Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Moyle","sequence":"additional","affiliation":[{"name":"St Stephen's AIDS Trust, Chelsea and Westminster Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2016,2,1]]},"reference":[{"key":"bibr1-IMP3098","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062744"},{"key":"bibr2-IMP3098","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.15.2.17426"},{"key":"bibr3-IMP3098","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-2013"},{"key":"bibr4-IMP3098","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200203290-00002"},{"key":"bibr5-IMP3098","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200411050-00005"},{"key":"bibr6-IMP3098","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000244200.11006.55"},{"key":"bibr7-IMP3098","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200403050-00008"},{"key":"bibr8-IMP3098","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2011.0327"},{"key":"bibr9-IMP3098","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200204120-00005"},{"key":"bibr10-IMP3098","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835b2ef1"},{"key":"bibr11-IMP3098","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1675"},{"key":"bibr12-IMP3098","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.22.1.112"},{"key":"bibr13-IMP3098","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.1979.237.3.E214"},{"key":"bibr14-IMP3098","doi-asserted-by":"publisher","DOI":"10.3851\/IMP1518"},{"key":"bibr15-IMP3098","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181da1287"},{"key":"bibr16-IMP3098","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ193"},{"key":"bibr17-IMP3098","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32833a608a"},{"key":"bibr18-IMP3098","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32834f3507"},{"key":"bibr19-IMP3098","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-014-0175-4"},{"key":"bibr20-IMP3098","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00550.2006"},{"key":"bibr21-IMP3098","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181c190f4"},{"key":"bibr22-IMP3098","doi-asserted-by":"publisher","DOI":"10.2310\/JIM.0b013e3181641b26"},{"key":"bibr23-IMP3098","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328359f29c"},{"key":"bibr24-IMP3098","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32832ba904"},{"key":"bibr25-IMP3098","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ327"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3098","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3098","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:52:08Z","timestamp":1777380728000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3851\/IMP3098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,1]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.3851\/IMP3098"],"URL":"https:\/\/doi.org\/10.3851\/imp3098","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,1]]}}}